The definitive destination for generic medicines in India — covering Jan Aushadhi, biosimilars, CDSCO regulation, affordable healthcare, and India's extraordinary role as the pharmacy of the world.
Branded vs Generic — India
Metformin 500mg
Anti-diabetic · 10 tablets
Atorvastatin 10mg
Cholesterol · 10 tablets
A generic medicine contains the same active pharmaceutical ingredient (API) as its branded equivalent — at the same dosage, strength, and route of administration. The only difference is price. Under patent expiry, any manufacturer can produce the same molecule legally.
India is the world's most consequential supplier of generic medicines — manufacturing 60% of the world's vaccines, 40% of all US generics, and nearly a third of UK medicines. GenericRx.in is the authoritative digital home for this transformative industry.
Bioequivalent — Not Inferior
Generics must demonstrate bioequivalence to the original — same absorption, same effect, same safety — under CDSCO regulation. They are medically identical to their branded counterparts.
50–90% Cheaper
Without the cost of original R&D and brand marketing, generic manufacturers can price their products at a fraction of branded equivalents — passing savings directly to patients.
India Supplies the World
Indian generic manufacturers — Sun Pharma, Cipla, Dr. Reddy's, Lupin, Aurobindo — supply life-saving medicines to patients in 200+ countries, often at the only price they can afford.
"Affordable medicines are not a luxury — they are a fundamental right. Jan Aushadhi is India's most important public health initiative of the last decade."
India's Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) — Jan Aushadhi — is the government's flagship programme to make quality generic medicines available to every citizen at up to 90% below market price, through a network of over 11,000 dedicated pharmacies.
// Pradhan Mantri Bhartiya Janaushadhi Pariyojana
Jan Aushadhi: 11,000 Kendras. 2,000+ Medicines. One Mission.
India's Jan Aushadhi network has saved patients an estimated ₹30,000+ crore since inception — making it one of the world's most successful generic medicine access programmes. GenericRx.in is the definitive digital companion for patients, doctors, and pharmacists navigating this ecosystem.
Switching from branded to generic medicines for common chronic conditions can save the average Indian patient ₹15,000–₹40,000 annually. GenericRx.in makes that information accessible to every patient, doctor, and pharmacist in India.
Metformin 500mg
₹85 → ₹10 (10 tabs)
88%
Pantoprazole 40mg
₹120 → ₹15 (10 tabs)
87%
Atorvastatin 10mg
₹110 → ₹20 (10 tabs)
82%
Amlodipine 5mg
₹75 → ₹10 (10 tabs)
87%
Amoxicillin 500mg
₹90 → ₹18 (10 tabs)
80%
Telmisartan 40mg
₹100 → ₹14 (10 tabs)
86%
GenericRx.in sits at the convergence of Indian pharma, digital health, and affordable medicine access — making it strategically valuable to a remarkably wide range of buyers.
A D2C platform selling generic medicines online — the fastest-growing pharma segment in India. GenericRx.in is the most credible, SEO-authoritative domain for this category.
A digital companion for India's Jan Aushadhi network — helping patients find their nearest Kendra, check medicine availability, and compare savings vs branded alternatives.
India's leading generic manufacturers — Sun Pharma, Cipla, Dr. Reddy's, Lupin — seeking a category-defining digital brand for their domestic consumer-facing generic portfolio.
A health-tech platform helping doctors prescribe generics, patients find them, and pharmacies stock them — addressing India's chronic under-prescription of generic equivalents.
Corporate health insurance and employee benefits platforms embedding generic substitution programmes — the fastest ROI lever in Indian employer healthcare cost management.
An editorial platform educating patients, doctors, and policymakers on generic medicine access — a high-traffic, high-trust content destination with strong SEO and monetisation potential.
India is the world's pharmacy. GenericRx.in is the world's pharmacy's most important digital address — covering a market where access, affordability, and authority all converge.
Exact-Match, Universally Understood Domain
GenericRx.in combines two terms every Indian patient, doctor, and pharmacist immediately understands. No brand-building required — the domain is its own message.
India Supplies 200+ Countries
India's pharmaceutical export value exceeds $25B annually. Generic medicines are 20% of global exports. The domain is relevant not just domestically — it has global reach through the Indian pharma brand.
12%+ Growth in India's Generic Pharma Market
Driven by Jan Aushadhi expansion, Ayushman Bharat, digital pharmacy growth, and rising generic prescription rates among urban doctors — the tailwinds are structural and durable.
Six Distinct High-Value Acquirer Types
Online pharmacies, Jan Aushadhi operators, generic manufacturers, healthtech startups, insurance platforms, and media brands — all have a compelling strategic case to own this domain.
India manufactures over 60,000 generic brands across 60 therapeutic categories. It supplies 60% of global vaccines, 40% of US OTC generics, and medicines to every country in the world. GenericRx.in is the digital infrastructure this extraordinary industry has been missing.
A plain-English guide to what generic medicines are, why they're as safe and effective as branded equivalents, and how they're regulated under CDSCO in India.
Read guide → // Jan AushadhiEverything you need to know about India's Jan Aushadhi scheme — how it works, which medicines are available, how to find your nearest kendra, and how much you can save.
Read guide → // For DoctorsIndia's MCI and NMC guidelines on generic prescribing, how to counsel patients, bioequivalence standards, and the most common generic substitution queries from patients.
Read guide →How India became the pharmacy of the world — covering the API ecosystem, formulation clusters, top manufacturers, export markets, and the regulatory framework under CDSCO.
Read guide → // BiosimilarsBiological medicines coming off patent represent a trillion-dollar global opportunity. India's biosimilar manufacturers — Biocon, Serum Institute, Zydus — are already leading. A complete guide.
Read guide → // PolicyHow Ayushman Bharat, Jan Aushadhi, the National List of Essential Medicines, and PM-JAY are collectively reshaping India's pharmaceutical access ecosystem and what it means for the industry.
Read guide →GenericRx.in is the definitive domain for generic medicines in the world's largest producer and exporter of generic pharmaceuticals. A category-exact, two-word domain on India's ccTLD — combining the most searched pharma keyword ("generic") with the universal medicine identifier ("Rx") — at the moment India's generic medicine market is entering its highest-growth decade.
India's annual pharmaceutical export value — 80%+ of which are generic medicines, supplying 200+ countries worldwide.
Government-backed generic pharmacies across India — the world's largest network of dedicated generic medicine retail points.
Generic medicines can cost up to 90% less than their branded equivalents — the most compelling consumer value proposition in healthcare.
Online pharmacies, Jan Aushadhi operators, manufacturers, healthtech, insurance, and media — six high-value buyer types with compelling strategic cases.